NDRM


Oppenheimer Raises Neuroderm Price Target Following ND0612 Phase 2 Update

Oppenheimer analyst Akiva Felt maintained an Outperform rating on Neuroderm (NASDAQ:NDRM) and slightly raised his price target to $19 (from $18), which implies …

Roth Capital Reiterates Buy On Neuroderm On The Back Of Phase 2a Data In Parkinson’s Disease

In a research report issued today, Roth Capital analyst Scott Henry reiterated a Buy rating on Neuroderm (NASDAQ:NDRM) with a $17.50 price target, …

IPO Preview: NeuroDerm

SummaryNDRM is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system, or CNS, disorders through proprietary formulations based on existing drugs …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts